Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Sopharma AD is a Bulgarian pharmaceutical manufacturer and distributor operating across Central and Eastern Europe, with production facilities in Sofia and distribution networks spanning the Balkans. The company manufactures generic pharmaceuticals, over-the-counter medications, and dietary supplements while also operating wholesale distribution channels. Recent performance shows revenue growth offset by margin compression, with the stock down 32% over the past year amid operational challenges.
Sopharma generates revenue through vertically integrated pharmaceutical operations: manufacturing generic drugs at cost advantages due to lower Bulgarian labor and facility costs, then distributing through owned wholesale channels across CEE markets. The 21.3% gross margin reflects competitive generic drug pricing pressure and distribution economics. Operating leverage is constrained by dual manufacturing and distribution cost structures. Competitive positioning relies on regional market knowledge, established distribution relationships with pharmacies, and regulatory approvals in multiple CEE jurisdictions rather than patent-protected products.
Bulgarian lev and regional currency movements against the euro (impacts input costs and export competitiveness)
Generic drug pricing dynamics in CEE markets and government reimbursement rate changes
Manufacturing capacity utilization rates and new product launch pipeline
Wholesale distribution volume growth across regional pharmacy networks
Raw material and active pharmaceutical ingredient (API) procurement costs
Generic drug pricing pressure from government cost containment initiatives across CEE healthcare systems and increased biosimilar competition
Regulatory complexity managing pharmaceutical manufacturing licenses and distribution permits across multiple CEE jurisdictions with varying compliance requirements
Consolidation in European pharmaceutical distribution creating larger competitors with superior scale economics
Competition from multinational generic manufacturers (Teva, Mylan/Viatris) with broader product portfolios and lower cost structures
Regional pharmaceutical distributors with deeper local market penetration and exclusive pharmacy network agreements
Vertical integration by pharmacy chains reducing reliance on third-party wholesale distributors
Negative free cash flow of -$0.0B and 1.31x current ratio indicate working capital strain and limited financial flexibility for growth investments
Currency exposure to Bulgarian lev fluctuations affecting euro-denominated debt or payables without natural hedges
Inventory obsolescence risk from generic drug expiration dates and changing formulary preferences
moderate - Pharmaceutical demand is relatively inelastic as healthcare needs persist through cycles, but discretionary OTC and supplement sales correlate with consumer purchasing power. Distribution volumes track pharmacy traffic and prescription rates. CEE economic growth drives healthcare spending and government reimbursement budgets. The -19.8% net income decline despite 12.8% revenue growth suggests margin pressure from input cost inflation outpacing pricing ability.
Moderate sensitivity through multiple channels: 0.30x debt/equity indicates manageable leverage, so financing costs are not primary concern. However, rising rates in Europe affect valuation multiples for low-growth healthcare distributors and impact working capital financing costs for inventory and receivables. Higher rates also strengthen the euro relative to Bulgarian lev, affecting import costs for APIs and raw materials sourced from Western Europe or Asia.
Moderate exposure through pharmaceutical distribution business model requiring extended payment terms to pharmacy customers (typical 60-90 day receivables in CEE markets). Tightening credit conditions could stress pharmacy customer payment cycles and increase bad debt provisions. Manufacturing operations require working capital for raw material inventory procurement, making access to trade credit lines important.
value - The 1.8x P/S and 2.1x P/B ratios suggest value orientation, though negative FCF and margin compression create concerns. The 14.7% ROE attracts investors seeking CEE healthcare exposure with regional growth potential, but -32% one-year return and operational challenges have driven away momentum investors. Dividend potential unclear given negative free cash flow.
high - The -33.3% three-month and six-month declines indicate elevated volatility. Small-cap CEE pharmaceutical stocks face liquidity constraints, currency volatility, and sensitivity to regional political/economic developments. Limited analyst coverage and Warsaw Stock Exchange listing add to price volatility compared to Western European healthcare peers.
